Pharmaceutical Executive-09-01-2012

Pharmaceutical Executive

Pharmaceutical Executive Digital Edition - September 2012

September 01, 2012

Issue PDF

0

0

Busting the Tape

The Power of Patient Feedback

September 01, 2012

Column

0

0

Specialized knowledge about disease and treatment is no longer the exclusive province of practicing physicians. Patient voices are increasing in volume, along with their roles in treatment decisions.

The Margin Call

September 01, 2012

From the Editor

0

0

Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.

Open Innovation in Pharma: Defining the Dialogue

September 01, 2012

Column

0

0

There is much talk today about "open innovation" in business and research forums-but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? Does it signal a change in the way pharmaceutical companies approach research and innovation?